Live ticker
Activity
Every trade on Endcap, live. The tape updates in place as new positions clear.
50 trades
- @blakevargasBoughtYESat 63¢+78 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @skylerunderhillBoughtNOat 25¢+250 SPon Most-funded GLP-1 weight-loss app of 2026: Hims Weight Loss
- @caseyokaforBoughtYESat 42¢+43 SPon Most-funded GLP-1 weight-loss app of 2026: Sequence (WW)
- @blakeunderhillBoughtNOat 34¢+49 SPon Most-funded GLP-1 weight-loss app of 2026: Found
- @jordanvargasBoughtNOat 43¢+56 SPon First GLP-1 brand to 1M active subscribers: Ro
- @micahbennettBoughtNOat 31¢+45 SPon First GLP-1 brand to 1M active subscribers: Calibrate
- @sashavargasBoughtYESat 62¢+37 SPon First GLP-1 brand to 1M active subscribers: Sequence
- @tatumchenBoughtYESat 40¢+54 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Eli Lilly (tirzepatide)
- @haydenlopezBoughtYESat 53¢+30 SPon Generic GLP-1 launch in US: Q3 2026
- @averylopezBoughtNOat 34¢+36 SPon Tirzepatide compounding outcome: Status quo (compounding continues)
- @sashavargasBoughtYESat 83¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Sequence (Weight Watchers)
- @frankieblakeBoughtYESat 59¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Found
- @parkerokaforBoughtYESat 59¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Hims
- @skylercarrilloBoughtYESat 62¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: Calibrate
- @darbyblakeBoughtYESat 52¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: PlushCare
- @blakeunderhillBoughtNOat 47¢+68 SPon Tirzepatide compounding outcome: Full ban with no shortage carve-out
- @rowanmonroeBoughtYESat 52¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: Ro
- @harperyoonBoughtYESat 57¢+60 SPon Tirzepatide compounding outcome: Expanded permissions
- @tatumwalshBoughtYESat 57¢+46 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @elliotalvarezBoughtYESat 49¢+27 SPon Most-funded GLP-1 weight-loss app of 2026: Other
- @juneyoonBoughtNOat 54¢+25 SPon Most-funded GLP-1 weight-loss app of 2026: Calibrate
- @haydenlopezBoughtNOat 53¢+65 SPon Tirzepatide compounding outcome: Restricted with shortage carve-out
- @logantorresBoughtYESat 71¢+60 SPon Generic GLP-1 launch in US: Q4 2026
- @kaiunderhillBoughtYESat 73¢+36 SPon Generic GLP-1 launch in US: Q2 2026
- @skylercarrilloBoughtYESat 45¢+69 SPon First GLP-1 brand to 1M active subscribers: Found
- @sagecarrilloBoughtNOat 44¢+38 SPon Generic GLP-1 launch in US: Q1 2026
- @skylerunderhillBoughtNOat 68¢+26 SPon Generic GLP-1 launch in US: 2027 or later
- @kaidiazBoughtNOat 34¢+62 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Eli Lilly (tirzepatide)
- @rowandiazBoughtNOat 46¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Ro
- @darbyblakeBoughtYESat 57¢+45 SPon First GLP-1 telehealth to raise a mega-round in 2026: Calibrate
- @skylerunderhillBoughtYESat 44¢+63 SPon First GLP-1 telehealth to raise a mega-round in 2026: PlushCare
- @sashahayesBoughtNOat 37¢+69 SPon Most-funded GLP-1 weight-loss app of 2026: Sequence (WW)
- @drewhayesBoughtYESat 52¢+43 SPon First GLP-1 telehealth to raise a mega-round in 2026: Found
- @briarlopezBoughtNOat 33¢+77 SPon First GLP-1 brand to 1M active subscribers: Calibrate
- @finleyyoonBoughtNOat 65¢+37 SPon Generic GLP-1 launch in US: Q3 2026
- @lanejensenBoughtNOat 57¢+71 SPon Most-funded GLP-1 weight-loss app of 2026: Calibrate
- @juneyoonBoughtNOat 48¢+80 SPon First GLP-1 brand to 1M active subscribers: Ro
- @rowandiazBoughtNOat 46¢+80 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Novo Nordisk (semaglutide)
- @parkersantosBoughtNOat 37¢+80 SPon First GLP-1 brand to 1M active subscribers: Found
- @parkerokaforBoughtNOat 56¢+32 SPon First GLP-1 brand to 1M active subscribers: No brand discloses
- @kaipatelBoughtYESat 63¢+67 SPon Lilly vs Novo: bigger GLP-1 share gain in 2026: Tied within 1pp
- @micahashworthBoughtNOat 52¢+80 SPon First GLP-1 telehealth to raise a mega-round in 2026: Hims
- @logantorresBoughtNOat 60¢+73 SPon Tirzepatide compounding outcome: Restricted with shortage carve-out
- @taylorvargasBoughtNOat 52¢+39 SPon Tirzepatide compounding outcome: Expanded permissions
- @rowandiazBoughtYESat 71¢+58 SPon Generic GLP-1 launch in US: Q2 2026
- @frankieblakeBoughtNOat 41¢+80 SPon Most-funded GLP-1 weight-loss app of 2026: Hims Weight Loss
- @alexkhanBoughtNOat 68¢+34 SPon Generic GLP-1 launch in US: Q4 2026
- @logantorresBoughtNOat 37¢+68 SPon Tirzepatide compounding outcome: Status quo (compounding continues)
- @lanewalshBoughtYESat 81¢+74 SPon First GLP-1 telehealth to raise a mega-round in 2026: Sequence (Weight Watchers)
- @emersonhayesBoughtNOat 48¢+55 SPon First GLP-1 telehealth to raise a mega-round in 2026: Found